Alzheimer's disease (AD) is an age-related neurodegenerative disease leading over the course of decades to the most common form of dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide (GIP) have been developed to treat type 2 diabetes and also act as growth factors. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Type 2 diabetes (T2D) and Alzheimer disease (AD) are two major health issues nowadays. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a devastating disease characterized by synaptic and neuronal loss in the elderly. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The findings in this report indicate that progress has been steady but slow for many of the priority health issues in the United States. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
40/100
Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS) and retinal degeneration have been studied extensively and varying molecular mechanisms have been proposed for onset of such diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Decreased olfactory function is very common in the older population, being present in over half of those between the ages of 65 and 80 years and in over three quarters of those over the age of 80 years. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In the CNS, iron in several proteins is involved in many important processes such as oxygen transportation, oxidative phosphorylation, myelin production, and the synthesis and metabolism of neurotransmitters. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
As the second most common age related neurodegenerative disease after Alzheimer's disease, the health, social and economic impact resulting from Parkinson's disease will continue to increase alongside the longevity of the population. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The ability to maintain a functional proteome, or proteostasis, declines during the ageing process. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) extracts a heavy societal toll. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Machine learning algorithms and multivariate data analysis methods have been widely utilized in the field of Alzheimer's disease (AD) research in recent years. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The QICDSS provides a way of producing population-based data on the chronic disease burden, health services and prescription drug uses. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent studies have been cautiously optimistic about declining trends in dementia prevalence and incidence. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Only about one-third of individuals with COPD in Ontario, Canada, received PFT to confirm their diagnosis; age, comorbidity, and physician factors appear to influence its use. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
There has been much evidence demonstrating the involvement of oxidative stress in the pathology of neurological disorders. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Intracellular protein trafficking plays an important role in neuronal function and survival. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Agitation was defined broadly as: (1) occurring in patients with a cognitive impairment or dementia syndrome; (2) exhibiting behavior consistent with emotional distress; (3) manifesting excessive motor activity, verbal aggression, or physical aggression; and (4) evidencing behaviors that cause excess disability and are not solely attributable to another disorder (psychiatric, medical, or substance-related). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
It was found that the acupuncture stimulation could modulate the DMN activity in AD. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
One challenge faced by many family members caring for persons with dementia is lack of information about how to take care of others and themselves. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recent advances in mobile devices have made profound changes in people's daily lives. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
39/100
Recent findings Intracranial hypotension occurs spontaneously, following (lumbar) dural puncture, accidental dural opening, or excessive surgical cerebrospinal fluid drainage. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Down syndrome (DS) is one of the most common causes of intellectual disability, owing to trisomy of all or part of chromosome 21. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer´s disease (AD) is a neurodegenerative disorder with no known cure and rapid rise in incidence. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →